Mirna Therapeutics Inc. (NASDAQ:MIRN) was up 4.2% during trading on Wednesday . The company traded as high as $2.64 and last traded at $2.50, with a volume of 65,980 shares trading hands. The stock had previously closed at $2.40.

A number of equities research analysts recently commented on MIRN shares. Zacks Investment Research cut shares of Mirna Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 18th. Citigroup Inc. cut shares of Mirna Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $7.00 to $4.50 in a research note on Tuesday, August 16th. Oppenheimer Holdings Inc. increased their price objective on shares of Mirna Therapeutics from $7.00 to $13.00 and gave the company an “outperform” rating in a research note on Tuesday, August 16th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $14.00 price target on shares of Mirna Therapeutics in a research note on Friday, May 13th. Finally, Leerink Swann cut shares of Mirna Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $10.00 to $4.00 in a research note on Monday, August 15th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $8.10.

The stock’s market cap is $52.09 million. The stock has a 50 day moving average of $3.88 and a 200-day moving average of $4.27.

Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.